OBJECTIVE To examine changes in glomerular hyperfiltration and other measures of kidney function in youth with type 2 diabetes treated with dulaglutide or placebo. RESEARCH DESIGN AND METHODS Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10–18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide. RESULTS Mean estimated glomerular filtration rate (eGFR) decreased from baseline to 26 weeks in participants treated with dulaglutide versus placebo (−5.8 vs. −0.1 mL/min/1.73 m2; P = 0.016). Decreases in eGFR were observed primarily in participants with baseline glomerular hyperfiltration. At 26 weeks, the prevalence of both glomerular hyperfiltration and proteinuria increased with placebo but decreased with dulaglutide (P = 0.014 and 0.004 vs. placebo, respectively). CONCLUSIONS Dulaglutide was associated with attenuated glomerular hyperfiltration and proteinuria in youth with type 2 diabetes. The impact of these changes on the risk of diabetic kidney disease is unclear.

中文翻译：

---

度拉鲁肽与青年 2 型糖尿病患者的肾小球高滤过、蛋白尿和蛋白尿：AWARD-PEDS 研究的事后分析


目的 检测接受度拉鲁肽或安慰剂治疗的 2 型糖尿病青年患者肾小球高滤过率和其他肾功能指标的变化。研究设计和方法 对 154 名患有 2 型糖尿病的青少年（10-18 岁）的肾脏实验室数据进行事后分析，这些青少年参加了度拉鲁肽的完整安慰剂对照血糖控制试验。结果 与安慰剂相比，接受度拉鲁肽治疗的受试者平均估计肾小球滤过率 (eGFR) 从基线下降至 26 周（−5.8 vs. -0.1 mL/min/1.73 m2；P = 0.016）。 eGFR 下降主要在基线肾小球高滤过的参与者中观察到。 26 周时，安慰剂组肾小球高滤过率和蛋白尿的发生率均增加，而度拉鲁肽组则降低（与安慰剂相比，P 值分别为 0.014 和 0.004）。结论 度拉鲁肽与 2 型糖尿病青年的肾小球高滤过减弱和蛋白尿相关。这些变化对糖尿病肾病风险的影响尚不清楚。